Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$40.91 USD
+0.47 (1.16%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $40.88 -0.03 (-0.07%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth D Momentum C VGM
Price, Consensus and EPS Surprise
AMPH 40.91 +0.47(1.16%)
Will AMPH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AMPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMPH
Amphastar Pharmaceuticals (AMPH) Stock Moves -1%: What You Should Know
Is Amphastar (AMPH) a Buy as Wall Street Analysts Look Optimistic?
AMPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amphastar Pharmaceuticals (AMPH) Registers a Bigger Fall Than the Market: Important Facts to Note
Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know
New Strong Sell Stocks for March 18th
Other News for AMPH
Amphastar Pharmaceuticals Poised for Growth: Strong Generic Pipeline and Strategic Marketing Drive Buy Rating
Commit To Buy Amphastar Pharmaceuticals At $22.50, Earn 18.5% Annualized Using Options
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Ascendis Pharma (ASND) and AMN Healthcare Services (AMN)
Needham Sticks to Its Hold Rating for Amphastar Pharmaceuticals (AMPH)
Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies